 |
 |

Transoral Laser Surgery of Supraglottic Cancer
Follow-up of 141 Patients
Heinrich Iro, MD;
Frank Waldfahrer, MD;
Annelore Altendorf-Hofmann, MD;
Manfred Weidenbecher, MD;
Rolf Sauer, MD;
Wolfgang Steiner, MD
Arch Otolaryngol Head Neck Surg. 1998;124:1245-1250.
Objective To determine the role of transoral laser resection of supraglottic carcinomas.
Design Retrospective unicenter study of the oncologic results of transoral carbon dioxide laser microsurgery for supraglottic carcinomas performed between February 1979 and December 1993. Median follow-up was 37 months.
Setting University hospital academic tertiary referral center.
Patients We reviewed the medical records of 141 patients (a consecutive sample of 131 men and 10 women; mean age, 60 years) with histologically proven supraglottic carcinomas undergoing transoral laser surgery, possibly in combination with neck dissection or radiotherapy. Stage distribution of patients was as follows: stage I, 23.4%; stage II, 25.5%; stage III, 16.3%; and stage IV, 34.8% (according to the Union Internationale Contre le Cancer staging system).
Main Outcome Measures Recurrence-free survival rates and local and regional recurrence rates.
Results Five-year recurrence-free survival rates were as follows: the whole case load, 65.7%; stage I, 85.0%; stage II, 62.6%; stage III, 74.2%; and stage IV, 45.3%, according to the Union Internationale Contre le Cancer staging system. The local and regional recurrence rates were 16.3% and 9.9%, respectively.
Conclusions The oncologic results of transoral carbon dioxide laser surgery are satisfying if clean surgical margins (R0 resection) can be reached. In patients in whom tumor-free margins are not achieved (R1 and R2 resection) and transoral revision is not possible, transcervical procedures (partial or total laryngectomy) should be performed. The indication for transoral supraglottic laryngectomy in T3 lesions should be considered with restraint.
From the Department of OtorhinolaryngologyHead and Neck Surgery, Saarland University, Homburg (Drs Iro and Waldfahrer); the Tumor Registry (Dr Altendorf-Hofmann) and the Departments of Otorhinolaryngology Head and Neck Surgery (Dr Weidenbecher), and Radiation Oncology (Dr Sauer), University of Erlangen-Nuremberg, Erlangen; and the Department of OtorhinolaryngologyHead and Neck Surgery, University of Goettingen, Goettingen (Dr Steiner), Germany.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Transoral Laser Microsurgery for Advanced Laryngeal Cancer
Hinni et al.
Arch Otolaryngol Head Neck Surg 2007;133:1198-1204.
ABSTRACT
| FULL TEXT
American Society of Clinical Oncology Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer
Pfister et al.
JCO 2006;24:3693-3704.
ABSTRACT
| FULL TEXT
Concurrent Chemoradiotherapy as the Most Appropriate Treatment for Most T3 Laryngeal Carcinomas
Enepekides
Arch Otolaryngol Head Neck Surg 2005;131:815-818.
FULL TEXT
Nonsurgical Treatment of Laryngeal Cancer
Weinstein et al.
NEJM 2004;350:1049-1053.
FULL TEXT
|